This month, we explore the latest research on treating multiple sclerosis with cannabis extract. Editor Matthew Kiernan speaks to John Zajicek, professor of Clinical Neuroscience, Peninsula College of Medicine and Dentistry, UK. (0.54)

Received wisdom is that if you are disabled shortly after a head injury, you are not going to see this improve. However Tom McMillan, professor of Clinical Neuropsychology, University of Glasgow, explains how he has shown long term outcomes are actually dynamic. (9.08)

And the Scheltens scale. If you work with dementia patients you’ve probably used this simple rating of hippocampal atrophy. Philip Scheltens, director of the Alzheimer Center, VU University Medical Center, Amsterdam, talks about how he put the scale together 20 years ago, and why it still underpins practice. (14.21)

See also:
Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial
Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates
Disability in young people and adults after head injury: 12–14 year follow-up of a prospective cohort